Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 20/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22370915 | 1.00 | AVPR1A (0.86) | AVPR1A | |
| SCHEMBL22370913 | 1.00 | AVPR1A (0.86) | AVPR1A | |
| SCHEMBL42369 | 1.00 | AVPR1A (0.86) | AVPR1A | |
| SCHEMBL28464247 | 1.00 | AVPR1A (0.86) | AVPR1A | |
| SCHEMBL28466518 | 1.00 | AVPR1A (0.86) | AVPR1A | |
| SCHEMBL19027368 | 0.94 | AVPR1A (0.84) | AVPR1A | |
| SCHEMBL19027092 | 0.94 | AVPR1A (0.84) | AVPR1A | |
| SCHEMBL13510853 | 0.94 | AVPR1A (0.86) | AVPR1A | |
| SCHEMBL13510850 | 0.94 | AVPR1A (0.86) | AVPR1A | |
| SCHEMBL20819219 | 0.93 | AVPR1A (0.75) | AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3681871-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | Azevan Pharmaceuticals, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10364236-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190099410-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2019-04-04 | — | — | US | disclosed |
| WO-2019055913-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-9376424-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| WO-2015148962-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| EP-2587919-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | Azevan Pharmaceuticals, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130109666-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | AZEVAN PHARMACEUTICALS, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| WO-2012003436-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | AZEVAN PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20100016274-A1 | BETA-LACTAM CANNABINOID RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-21 | — | — | US | disclosed |
| US-20090170825-A1 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | AZEVAN PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| WO-2008034032-A2 | BETA-LACTAM CANNABINOID RECEPTOR MODULATORS | AZEVAN PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007109615-A2 | β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS | AZEVAN PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2006102308-A2 | BETA-LACTAMYL VASOPRESSIN V1B ANTAGONISTS | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | AVPR1A 2948/4885 |
| US-20190099410-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | GPX4, CRH, TXN | AVPR1A 787/4885 |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | GPX4, CRH, TXN | AVPR1A 787/4885 |
| US-20100016274-A1 | BETA-LACTAM CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, FAAH2 | AVPR1A 511/4885 |
| US-20090170825-A1 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | GABBR1, GABBR2, ALAD | AVPR1A 362/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | AVPR1A 4/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | AVPR1A 4/4885 |
| US-10364236-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | AVPR1A 4/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | AVPR1A 2948/4885 |
| US-20130109666-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | GPX4, CRH, TXN | AVPR1A 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.